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ABSTRACT
The goal of this research was to use a distal signaling pathway analysis to
evaluate the extent of agonist independent constitutive signaling among orphan class-A G
protein coupled receptors (GPCRs). These receptors translate extracellular signals via
conformational change into intracellular activation of different G proteins and subsequent
second messenger synthesis. These small molecules regulate cellular biochemistry,
eventually leading to nuclear signaling that results in changes in gene expression. Some
GPCRs are capable of signaling in the absence of an activating ligand, a phenomenon
called constitutive activity that is inhibited via an “inverse-agonist”. The use of cAMP
dependent Luciferase expression is used to compare the canonical signaling of all five
wild-type Muscarinic Acetylcholine receptors and their constitutively active (CA) mutant
counterparts. All five members, both wild-type and CA, signaled via cAMP dependent
pathways, although only the CA mutants do so in the absence of an agonist. This
technique is then applied to 40 different orphan GPCRs for which an agonist is
unknown/not-present. This resulted in 75% (30 out of 40) scoring as constitutively active,
grouped into five different categories based on their response. The largest and most
significant group of 17 orphans inhibited cAMP dependent expression, both basal and
forskolin stimulated, by more than 40%, indicating activation of Gαi. In total, novel
findings of constitutive activity were found in 23 of the 40 Orphan receptors with results
otherwise in agreement with literature in most cases. Orphan receptors that were closely
related based on amino acid homology tended to have similar effects on gene expression.
These results suggest that identification of inverse agonists may be a fruitful approach for
categorizing these orphan receptors and targeting them for pharmacological intervention.
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1. INTRODUCTION

1.1. BACKGROUND
G protein coupled receptors (GPCR or GPR) comprise a large superfamily of
receptors characterized by a seven transmembrane domain structure and an ability to
activate intracellular transducer G proteins. Over 800 GPCRs in five main families have
been identified in eukaryotes on the basis of genomic sequence analysis [1]. These
receptors can be activated by hormones, neurotransmitters, odorants, light, or
pheromones (Figure 1.1). Orphan GPCRs are a group of receptors for which the
endogenous agonist is not known or remains unclear or in dispute. The application of
drug screening, binding assays, and second messenger profiling techniques has decreased
the numbers of orphan G protein coupled receptors from 150 in 2004 [2] and to as few as
77 in 2014 [3]. The first receptor to be “de-orphanized” (or “adopted”) was the serotonin
(5-HT1A) receptor [4]. This process continued with new methods that allowed high
throughput screening for endogenous activating molecules for the remaining orphan
receptors [5]. However, in recent years the rate of de-orphanization appears to be slowing
[6].
Muscarinic receptor subtypes (M1-M5) differ in the coupling to cellular effector
mechanisms. M2 and M4 receptors generally couple most efficiently to inhibition of
certain isoforms of adenylate cyclase lowering cytosolic cAMP levels as a consequence
of interactions with Gi transducer proteins, while M1, M3 and M5 couple most
efficiently to the stimulation of phospholipase C causing a mobilization of intracellular
calcium as a consequence of interactions with Gq/11 proteins [7-9]. This specificity is not
absolute and a myriad of signaling variations have been reported [10-13]. Thus, while
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Figure 1.1. Basic principle of GPCR-mediated signal transduction. A, Molecular
representation of a GPCR based on the x-ray crystal structure of rhodopsin. Helices 3 and
6 are shown in blue and green, respectively. B, Basic pattern of ligand-mediated GPCR
signal transduction. After ligand agonist binding, the receptor undergoes conformational
changes, which promotes the coupling with heterotrimeric G proteins (Gαβγ) and
catalyzes the exchange of GDP by GTP on the α-subunit. This event engages
conformational and /or dissociational events between the α- and βγ-subunits, and both
GTP-bound Gα-subunit and the Gβγ-dimer can then modulate the activity of various
effectors. For example, stimulation or inhibition of adenylyl cyclase (AC)-mediated
cAMP synthesis by the α-subunit of the Gs or Gi families, respectively; production of
inositol 1,4,5-triphosphate (IP3) and 1,2-diacylglycerol (DAG) after cleavage of
phosphatidylinositol 4,5-biphosphate (PIP2) by Gαq stimulation of phopholipase C
(PLC); activation of Gi and Go also mediated most of the Gβγ-mediated signaling
processes such as activation of GIRK. Directly from [14].

M2 receptors inhibit adenylate cyclase, they can (in appropriate systems and under
certain conditions) stimulate adenylate cyclase and phospholipase C[11,12]. M3
receptors can also stimulate adenylate cyclase at high agonist concentrations.
This multiplicity of actions reflects multiplicity of signal transduction effector
isoforms (e.g., 10 isoforms of adenylate cyclase), crosstalk between signaling pathways,
and cell type specific differences in the expression of signaling proteins. Crosstalk
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between pathways can take place at different levels: at the receptor level, signaling
potential is affected by the level of receptor expression [15]; at the transduction level, M2
receptors can directly activate multiple transducer G proteins (Gαi and Gαs) [11]; at the
second messenger level, cAMP, inositol trisphosphate, Ca2+, and diacylglycerol can
activate or inhibit protein and enzymes that in turn regulate both receptors and effector
molecules.
Signaling mediated by second messengers transiently regulates cell processes,
many of which lead to changes in transmembrane potential and thus electrical excitability
of the cell [16]. However, long term changes in cell behavior require the integration of
second messenger activity (proximal signaling) into changes in gene expression (distal
signaling) (Figure 1.2). Measurement of these second messengers can sometimes be
problematic, especially in the case of inhibitory pathway activation (ie. Gαi). Under these
conditions it is useful to artificially elevate second messenger (cAMP) levels in order to
more easily visualize the inhibition of that pathway. Forskolin (Figure 1.3), a diterpene
derivative, has been used previously for this purpose [17]. Acting as a potent stimulator
of adenylate cyclase, this compound increases the frequency and length of time that the
enzymatic site is formed via the binding of the two catalytic domains [18] (Figure 1.4).
While these two domains are in contact, the active site can catalyze the formation of
cAMP via Mg2+ assisted ring formation [19] (Figure 1.5). This activity is directly
opposed by the binding of inhibitory G proteins via a decrease in catalytic domain
affinity, thus decreasing the stimulatory effect of Forskolin [20].
The phenomenon of agonist-independent “constitutive” signaling (Figure 1.6) was
first observed with the delta opioid receptor in 1989 [21]. This was followed by the
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Figure 1.2. G protein signaling pathways. A schematic diagram showing how, after
stimulation of the GCPR and dissociation of the G-protein subunits, the major G-protein
families signal via the different intracellular second messenger pathways to communicate
with nuclear promoter elements. (a) Gαs-coupled receptors stimulate adenylyl cyclase
(AC), which synthesises cAMP from ATP. In contrast Gαi-coupled receptors inhibit AC
and so reduce cAMP formation. (b) The βγ subunits from Gαi and other G proteins are
able to activate the MAP kinase pathways and PLCβ. (c) GPCRs coupled to the Gαq
family of G proteins stimulate PLCβ, which cleaves membrane phospholipids to produce
IP3, which mobilises intracellular calcium, and DAG, which activates PKC. (d) Second
messenger pathways then activate a range of effector systems to change cell behaviour; in
many cases this includes the regulation of gene transcription. Dotted line shows a more
indirect pathway. MAPK, MAP kinase, MEK, MAP kinase kinase; P, phosphate; PIP2,
phosphatidylinositol-4,5-bisphosphate. Taken directly from [22].

discovery of mutant versions of other native GPCRs that signal in a similar manner [23].
Constitutive activity is now known to be present in a large number of GPCRs. As of this
publication, a PubMed search for “GPCR” and “constitutive” reveals 132 references
since 2010. Constitutive activity can be created in most Class-A GPCRs by slightly
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Figure 1.3. Structure of Forskolin. This molecule interacts directly with both
catalytic subunits of Adenlyate Cyclase to form the active site and increase cAMP [17].

Figure 1.4. Activity of Forskolin, Gαi and Gαs in regulating Adenylate Cyclase. The two
catalytic domains of Adenylate Cyclase normally have very low affinity for each other.
Formation of cAMP can only occur when these two domains bind together, forming the
active site. Forskolin, a diterpene binds to both C1 & C2 domains via hydrogen bonding
and hydrophobic interactions increasing their affinity. Gαs and Gαi work in antagonistic
fashion to increase or decrease affinity for the two catalytic domains respectively.
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Figure 1.5. Formation of cAMP is dependent on both catalytic domains. Coordination of
metal ions (Mg2+) allow for interactions between the two catalytic domains (C1 in green,
C2 in red). Conformational changes of individual residues during catalysis are marked.
Adapted from [19].

lengthening the sixth transmembrane domain [24]. Structural analyses of some receptors
suggest that this mutation eliminates interactions between hydrophobic amino acids on
the third and sixth transmembrane, leading to the formation of a water filled pore [25]
[26]. This led to a “unifying” theory on the biochemical mechanisms that regulate GPCR
activation, including the changes that may lead to constitutive signaling [27].
The use of constitutive signaling poses certain challenges. There is the risk that
endogenous ligands or activating conditions may be present in the testing media, thereby
confounding data interpretation, as was the case for the ADORA2 receptor [28].
Receptors can also respond differently under different conditions, either due to
promiscuous interactions with transducer elements, cellular conditions [29], or even
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Figure 1.6. Agonist vs. Constitutive activation of GPCR signaling. G protein coupled
receptors (GPCR, or GPR) are in a constant equilibrium between the inactive (R), and
active (R*) forms of the protein. The ratio of the two (R*/R) can be expressed as an
equilibrium constant. “Agonists” are ligands that act to destabilize the inactive form of
the receptor shifting the equilibrium to the active conformation, thus recruiting and
activating intracellular G proteins, which in turn activates downstream second messenger
synthesis/release. Constitutive activity occurs when the Keq of the native receptor is large
enough that the GPCR can activate signal cascades in the absence of a ligand. Inverse
Agonists are molecules that bind to the agonist active site but act as stabilizing agents for
the inactive form, thus shifting equilibrium away from the active state and preventing
activation of G proteins, even- if not especially, in constitutively active receptors.

hetero-dimerization with other native receptors [30]. Nevertheless, constitutive signaling
has been useful in the discovery of native ligands [31], and is a required for the
systematic search for inverse agonists.
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Constitutive signaling as a tool in orphan receptor characterization was reviewed
in 2006 [32]. The history of inverse-agonists (i.e., compounds that inhibit constitutive
activity) as a therapeutic approach has also been reviewed [33]. While the use of
constitutive signaling for drug discovery (notably, for inverse-agonists) has been
discussed [5], the use of constitutive signaling to de-orphanize or to understand potential
signaling pathways in GPCRs has not been widely exploited. Accordingly, this work was
developed to experimentally establish that distal signaling via a Luciferase linked
reporter vector could be used to measure and characterize cAMP dependent constitutive
activity among the largest collection of orphan class-A G protein coupled receptors to
date.

1.2. FORMAT
1.2.1. Section 2: Establishing the Assay. Experiments performed in this section
compared cross talk patterns in receptor signaling at distal levels of the signaling cascade.
Specifically, gene activation by muscarinic receptors (M1 – M5; GenBank AF498915-9)
possessing a wild type (WT) or constitutively active (CA) phenotype were examined.
Comparing signaling pathways of known receptors (M1-M5) with known responses vs.
the characterization of constitutively active mutant (CAM) receptors of the same family
established the validity of the assay and supported its use in the characterization of
unknown orphan receptors.
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1.2.2. Section 3: Constitutive Signaling Among Orphan Receptors. The
prevalence of constitutive activity among Class-A orphan GPCRs has
not been comprehensively examined. Experiments performed in this section examined 40
class-A orphan G protein coupled receptors to determine the prevalence of cAMP
dependent constitutive signaling (i.e., signaling that is generally mediated by Gαi and Gαs
transducer proteins), using receptor activation or inhibition of gene expression under
control of the cAMP-dependent response element (CRE) as the indicator of pathway
activation.
1.2.3. Section 4: Summary, Discussion, and Impacts. Considering the nature of
the subject under evaluation, an initial “Review of Literature” option would not be
appropriate. This section provides an individual review of the literature on each orphan
GPCR examined within this work and discusses the results of experiments performed.
Indications of agreement/disagreement with established receptor behavior is noted, as
well as the contribution of this work towards that body of knowledge.

10
2. ESTABLISHING THE ASSAY

2.1. METHODS
2.1.1. Cell Culture. CHO-K1 wild-type Chinese hamster ovary (CHO) cells
were obtained from the American Type Culture Collection (ATCC). CHO cells stably
transfected with the coding sequences for M2 or M3 muscarinic receptor (CHO-M2 and
CHO-M3; GenBank AF498916; GenBank AF498917, respectively) were obtained from
the cDNA Resource Center (www.cdna.org). Cells were maintained at 37oC with 5%
CO2. Culture media consisted of 90% HyClone DMEM (without phenol red or additional
L-glutamine) supplemented with 10% HyClone FetalClone II (bovine serum product).
Plates were allowed to reach 80% confluency before being split for growth or use in
subsequent experiments.
2.1.2. CRE Regulated Gene Expression. A luciferase coupled reporter vector
(Promega) was used to monitor CRE regulated gene expression in CHO cells. CHO cells
in (200,000 in 100 µl media) were plated onto 96-well plates and incubated until they
reached 80% confluency. Cells were mixed with firefly luciferase reporter vector
(Promega) at a final concentration of 250 ng per well and Lipofectamine 2000 Reagent
(Invitrogen), following manufacturer’s suggested protocols. In some experiments, CHO
cells were co-transfected with clones for a specific subtype of muscarinic receptor (M1 –
M5) possessing either a wild type (WT) or constitutively active (CA) phenotype in a
pcDNA3.1+ vector (Invitrogen) obtained from the cDNA Resource Center
(www.cdna.org), and incubated for 24 hours. Transfection with an empty pcDNA3.1+
vector served as a control. In other experiments, the reporter gene vector was transfected
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into CHO cells stably expressing a muscarinic receptor cDNA clone (obtained from the
cDNA Resource Center; www.cdna.org).
Transfection media was removed and replaced with complete media. The plate
was then incubated for an additional 6 hours. Immediately prior to visualization, each
well was rinsed with PBS and replaced with 50ul of DMEM (-phenol red) without serum.
Controls and treatments intended to test Gαi signaling (i.e., inhibition of adenylate
cyclase) were exposed to 3 µM forskolin (Sigma Aldrich) to activate the catalytic subunit
of the cyclase. Imaging was performed using a FLUOstar Omega (BMG Labtech) 96well plate reader. Auto-injection of 25ul of Bright-Glo Luciferase Reagent (Promega)
was followed by 2 minutes of rotary incubation. Relative Light Units (RLUs) were
measured in each well for 1 minute. Each plate was repeated in triplicate and contained
12 treatment groups with 4 replicates in each group, separated by a row of unused wells
to minimize light pollution. Control treatments (3 µM forskolin stimulated cells with
CRE-Luciferase and empty pcDNA3.1+) were used to standardize RLU values between
plates.
2.1.3. Data Analysis. Experiments were performed 3-8 times in triplicate or
quadruplicate. Data is expressed as the mean and standard deviation from the
independent experiments. Measurements from two populations (e.g., wild type vs.
constitutively active receptors) were compared using Student’s t-test. Values from
experiments with multiple independent variables (e.g., concentration curves) were
compared by ANOVA and Tukey’s test using GraphPad Prism software. Significant
differences were indicated by P values of < 0.05.
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2.2. RESULTS
2.2.1. Activation of Gene Expression Under Control of the cAMP Response
Element (CRE) in CHO-M2 Cells. Dose-response curves for forskolin induced gene
expression mediated by CRE were determined. Direct enzymatic activation by forskolin
was not affected by receptor expression (i.e., was identical in wild type, M2-expressing
and M3-expressing CHO cells). The concentration relationship for forskolin activation
depended on the length of exposure to forskolin (Fig 2.1). When exposed to forskolin for
15 minutes followed by removal by washing, gene expression 6 hours later was increased
by forskolin only at concentrations above 10 µM (Figure 2.1.A). When the forskolin was
not removed from the incubation medium, the threshold was 30 fold lower (≈ 0.3 µM).
These effects of forskolin were independent of receptor expression. Thus, emphasizing
that gene expression assays provide a valid and reliable means of characterizing distal
GPCR signaling.
CHO-M2 cells potentiate adenylate cyclase at 100uM of Carbamylcholine, showing
increased expression of luciferase under control of the CRE. The increase in reporter
gene expression in response to 100 µM carbamylcholine was significant within 2.5 hours
and peaked after 8 hours (Figure 2.1.B). In subsequent expressions, a 6 hour incubation
period was routinely used.
2.2.2. CRE-Mediated Gene Expression Stimulated by each WT and CA
Muscarinic Receptor Subtype; Distal Receptor Signaling is Potentiated by
Constitutive Activity. Luciferase reporter assays were used to compare second
messenger signaling with signaling patterns integrated at the gene expression level in
each of the five muscarinic receptor subtypes with either a wild type or constitutively
active phenotype.
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A

B

Figure 2.1. Carbamylcholine and forskolin activation of CRE-mediated expression of a
reporter gene in CHO-WT cells. RLU, relative luminescent units.
Figure 2.1.A. CHO wt cells were incubated with the indicated concentrations of
forskolin. In the “Acute” condition, the cells were exposed to forskolin for 15 min and
then the forskolin was removed by replacing the media; in the “Chronic” condition,
forskolin was present throughout the 6 hour incubation.
Figure 2.1.B. CHO-M2 cells were incubated with 100 µM carbamylcholine for the
indicated times before measuring luminescence catalyzed by reporter gene generated
luciferase. Subsequent experiments were performed using a 6 h incubation.

Constitutively active muscarinic receptors were created by inserting two amino acids
into the sixth transmembrane domain. This alteration conveys a constitutively active
phenotype in many G protein coupled receptors [24], possibly by disrupting a
hydrophobic lock structure that involves elements of the 6th and 3rd transmembrane
domains[25-27]. Constitutive activity was associated with a higher level of basal CREmediated gene expression with all 5 receptor subtypes, although M3 receptors showed the
greatest fractional response (≈ 700%) and M2 and M4 showed the lowest fractional
responses (≈ 100%) (Figure 2.2). Carbamylcholine increased expression mediated by all
CA receptors subtypes except M4. The greatest increases (and lowest basal activities)
were seen with M1, M3 and M5 CA receptors.
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Figure 2.2. Stimulation of CRE-mediated gene expression by activation of the five
muscarinic receptor subtypes with either a wild type (WT) or constitutively active (CA)
phenotype. CHO cells were transiently transfected with genes for each of the muscarinic
receptors subtypes (M1 – M5, WT or CA). Activity was measured 24 h later in the
absence or presence of 100 µM carbamylcholine and is expressed as relative
luminescence units normalized to activity measured in the presence of 3 µM forskolin.
Mean ± SD; N = 4. Carbamylcholine increased expression mediated by all WT receptors
subtypes except M4; receptors with constitutive activity had greater activity than wild
type receptors of the same subtype; carbamylcholine further increased the activity of all
subtypes with a CA phenotype, except M4 (all comparisons by Student’s t-test; p < 0.05).

2.2.3. Agonist Concentration Dependence of CRE-Mediated Gene Expression
Stimulated by WT and CA M2 and M3 Muscarinic Receptors. CRE mediated gene
expression assays were used to further characterize the signal transduction potential of
M2 and M3 (WT and CA) receptors, since these two receptors exhibit the strongest
activation in the classes of receptor subtypes (i.e., Gi- and Gq/11-coupled receptors).
Basal levels of CRE-mediated gene expression were more than doubled in the CHO cells
expressing M2 or M3 receptors with a CA phenotype (Figure 2.2). CRE-mediated
activity was further increased by carbamylcholine in cells expressing either the M2 or M3
CA receptors; dose responses curves for these relationships are presented in Figure 2.3.

15

Figure 2.3. Influence of constitutively active (CA) phenotype on stimulation of CREmediated expression in cells transiently expressing M2 (left) and M3 (right) receptors.
Activity is expressed as relative luminescent units normalized to background
luminescence (sham reporter gene transfection) and the response obtained at the highest
agonist concentration. Basal levels of CRE-mediated gene expression were 123 ± 21%
and 115 ± 26% greater in the cells expressing M2 and M3 receptors with a CA
phenotype, respectively (p < 0.05; N = 3; Student’s t-test). Mean ± SD from 4
determinations from a typical experiment repeated 5 (M2) or 3 (M3) times with
essentially similar results.

CA M2 receptors, but not CA M3 receptors responded to carbamylcholine with a lower
threshold than the corresponding WT receptors.
2.2.4. Concentration-Dependent Inhibition and Activation of CRE Mediated
Gene Expression by M2 Receptors. It is generally recognized that M2 receptors
preferentially activate Gi proteins thereby attenuating adenylate cyclase activity[7-9]. It
is readily apparent form the experiments depicted in Figures 2.1, 2.2, and 2.3 that M2
receptor subtypes can also stimulate adenylate cyclase activity and CRE-mediated gene
expression at high concentration of agonists. As shown in Figure 2.4 the nature of these
responses illustrates the concentration dependence of carbamylcholine stimulated gene
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Figure 2.4. Carbamylcholine inhibition/stimulation of CRE-mediated gene expression of
luciferase in CHO-M2 cells. Activity is expressed as relative luminescent units
normalized to the response produced by a maximally effective concentration of
carbamylcholine. Measurements were made in the absence (Control) and presence of 0.6
µM forskolin, as indicated. Mean ± SD from 4 determinations from a typical experiment
repeated 4 times with essentially similar results. Carbamylcholine attenuated gene
expression in the presence of forskolin at 1 and 10 nM (ANOVA; p < 0.05), but the EC50
values for carbamylcholine activation of response in the two conditions were not
different. Inhibition of forskolin stimulation under low concentrations of carbamylcholine
show Gα-i signaling.

expression under control of CRE in CHO-M2 cells was determined. Carbamylcholine
activated gene expression following a 6 hour incubation with an EC50 of ≈ 30 µM. While
inclusion of 0.6 µM forskolin in the incubation medium increased the response at higher
agonist concentrations by ≈ 40%, an inhibition of response was revealed at very low
concentrations of carbamylcholine (1-10 nM), presumably reflecting Gmediated
inhibition of adenylate cyclase. This result is consistent with previous observations in
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literature cited above and further demonstrates the close correlation between M2 receptor
alterations of CRE mediated gene expression and cAMP production.

2.3. DISCUSSION
Activation of the G protein-coupled muscarinic receptors leads to relatively rapid
changes in transmembrane potential through modulation of ion channels and transporters,
either directly or through second messenger-mediated events [16]. Activation of the same
receptors also leads to changes in gene expression mediated by second messenger
activation of kinase cascades whose targets include transcription factors. The purpose of
these experiments was to increase understanding of crosstalk signaling in muscarinic
systems and to establish the efficacy of this experimental assay in characterization of
constitutively signaling receptors. Specifically, this work compared crosstalk in distal
signaling events (second messenger production causing altered gene expression), to
evaluate the persistence of cross talk signaling in receptors with a constitutively active
phenotype, and to evaluate the potential for these effects in all 5 receptor subtypes which
represent multiple signaling profiles.
2.3.1. Canonical Muscarinic Signaling in CHO Cells. CHO cells are a widely
used model system in biomedical research, including cellular signaling pathways, due to
their robust growth and amenability to transfection and expression of recombinant
proteins. In wild-type CHO cells, acetylcholinesterase activity, muscarinic receptor
binding, or muscarinic signaling is not detected in either calcium mobilization or
alteration of cAMP synthesis in response to the muscarinic agonist carbamylcholine.
However, CHO cells express components of both the phospholipase C (influencing AP1 and NFAT) [34,35] and adenylate cyclase (CRE) [36] signaling pathways, and CHO
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cells transfected with transgenes for the different muscarinic receptor subtypes respond to
muscarinic agonists in pharmacologically and physiologically appropriate manners:
Activation of human M1, M3 or M5 receptors expressed in CHO cells leads to the
production of IP3, release of calcium from the ER, activation of store-operated calcium
entry, and modulation of the expression of genes under their control. Activation of human
M2 and M4 receptors expressed in CHO cells leads to the inhibition of forskolinstimulated cAMP formation and alteration of the expression of genes under the control of
the cAMP response element (CRE) [36].
2.3.2. Crosstalk in Muscarinic Signaling. A myriad of studies have shown that
M2 and M4 receptors couple efficiently to Gi transducer proteins to inhibit adenylate
cyclase, while M1, M3 and M5 couple more efficiently to the stimulation of
phospholipase C as a consequence of interactions with Gq/11 proteins[7-10]. Crosstalk
at this level of the signal transduction cascade encompasses the ability of specific
receptors to interact with different transducer G proteins, thereby activating different
pathways. The factors that affect receptor/G protein coupling status are incompletely
understood, but in experimental systems include identity and concentration of the agonist
as well as receptor/G protein stoichiometry [11,12,15].
M2 receptor activation inhibits forskolin-stimulated cAMP formation at relatively
low (EC50 ≈ 0.1 µM) but stimulated adenylate cyclase activity at high concentrations (>
100 µM). This is consistent with earlier studies [11]. Clearly, M2 receptors have an
intrinsic ability signal through either pathway. As a consequence of this crosstalk
signaling, M2 activation increases gene expression under the control of the CRE, even at
concentrations at which an increase in cAMP production is not apparent. In the presence
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of forskolin, a decrease in CRE-mediated gene expression is evident [11], paralleling the
inhibition of cAMP production. Thus, the major features of M2 – Gi crosstalk seen at
the level of adenylate cyclase regulation are also evident at the level of regulation of gene
expression.
Many class A GPCRs can be endowed with constitutive activity by slightly
lengthening the sixth transmembrane domain [24]. Structural analyses of muscarinic
receptors suggest that this mutation eliminates interactions between hydrophobic amino
acids on the 3rd and 6th transmembrane, leading to the formation of a water filled pore
[25-27]. M2 receptors with constitutive activity thus conferred mediate enhanced
crosstalk signaling through the Gs pathways.
A CA-inducing mutation increases CRE-mediated gene expression activity of all
muscarinic receptor subtypes. This is of course expected with M1, M3 and M5 receptors,
but was equally evident with M2 and M4 receptors. Moreover, carbamylcholine further
activated CRE-mediated gene expression of all muscarinic receptors subtypes except M4.
This suggests that the degree of receptor activation by CA-inducing mutation is less that
that produced by a receptor agonist. These measurements were preformed following
transient expression of the CA receptor variants. Attempts to produce a stably transfected
cell line constitutively expressing increased cAMP levels were met with no success.

2.4. CONCLUSIONS
Muscarinic receptors activate both preferred and secondary signaling pathways
through activation of different G proteins. Both M2 (preferred signaling through Gi) and
M3 (preferred signaling through Gq/11) activated adenylate cyclase (Gs signal) at high
agonist concentrations, and these increases in cAMP resulted in upregulation of distal
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reporter gene expression under control of the cAMP-dependent response element. These
results demonstrate that gene expression assays are a viable and reliable means to
characterize receptor-signaling pathways, and reveal similar promiscuity of receptors
with respect to signaling pathway.
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3. CONSTITUTIVE SIGNALING AMONG ORPHAN RECEPTORS

3.1. METHODS
Histamine, Muscarinic and Orphan GPCR receptor genes, cloned into
pcDNA3.1+ (Life Technologies) were acquired from the MS&T cDNA Resource Center
(www.cdna.org). These constructs were transiently co-transfected with Luciferase
coupled reporter vectors to monitor CRE dependent gene expression. Each experimental
treatment involved 4 wells seeded with 40,000 CHO-K1 cells in 96-well plates and
incubated for 24 hours. Experiments were repeated 4 to 8 times. An “empty” plasmid
(pcDNA3.1+) was used as a transfection negative control. Forskolin (3µM) mediated
stimulation of adenylate-cyclase served as a positive control for the assay and
additionally was used to normalize responses across experiments. Forskolin was
administered 6 hours prior to measurements concurrently with sham dosing (media)
where appropriate. Receptor activity was reflected by induction of luciferase expression
under the control of the cAMP response element (CRE).
3.1.1. Cell Culture. CHO-K1 wild-type Chinese hamster ovary cells were
obtained from the American Type Culture Collection (ATCC) and maintained at 37oC
with 5% CO2 as previously described [37]. Culture media consisted of 90% HyClone
DMEM (without phenol red or additional L-glutamine) supplemented with 10% HyClone
FetalClone II (bovine serum product). Plates were allowed to reach 80% confluency
before splitting or for use in subsequent experiments.
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3.1.2. Transfection. Approximately 40,000 CHO-K1 cells in 100 µl of media
were plated onto a 96-well plate and allowed to attach overnight and incubated until they
had reached 80% confluency. Firefly Luciferase reporter vector (pGL4.29, Promega)
was mixed with plasmid DNA containing orphan receptor GPCR coding sequences
(Missouri S&T cDNA Resource Center, www.cdna.org) or an empty pcDNA3.1+ vector
(Life Technologies) at a final concentration of 250 ng each per well. Transfection was
carried out following manufacturer’s suggestions (Lipofectamine 2000 Reagent, Life
Technologies), followed by an 18 h incubation before use.
3.1.3. Luciferase Assay. Transfection medium was removed and replaced with
complete medium. Controls and treatments intended to evaluate inhibition of the cAMP
pathway (i.e., putative Gα-i signaling) were treated with 3.0 µM Forskolin (Sigma
Aldrich). The plate was then incubated for an additional 6 hours. Immediately prior to
visualization, the medium within each well was replaced with 25 µl of DMEM (-phenol
red) without serum.
Imaging was performed using a FLUOstar Omega (BMG Labtech) 96-well plate
reader. Auto-injection of 25ul of Bright-Glo Luciferase Reagent (Promega) was followed
by 2 minutes of rotary incubation. Relative Light Units (RLUs) were obtained for each
well in series over 1 minute. Each 96-well plate consisted of 12 treatment groups with 4
replicates in each group. Each treatment group was separated by a row of unused wells to
minimize light pollution.
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3.1.4. Data Analysis. Statistical analysis was performed in MiniTab, version 17,
using a randomized complete block design. This variant of an ANOVA analysis takes
differences between experiments (plates/blocks) into account and also allows for
examination of treatment-block interaction. This statistical analysis allows for a strong
isolation of treatment effect within the experiments.
Each experimental group (n=4) was divided by the average of the positive control
treatments (3 µM Forskolin stimulated cells with CRE-Luciferase and empty
pcDNA3.1+, n=4) to normalize results between plates. Each experimental treatment was
then divided by its control (+/- 3 µM Forskolin) to determine the fractional stimulation or
inhibition. Data was graphed as the average percent change over control between 4 to 8
plates with the over-all treatment p-value for each comparison indicated via either a
single star for a threshold of 0.05, or a double star indicating a threshold of 0.01.
Treatment effects that did not meet either of these thresholds were displayed individually
and in red.

3.2. RESULTS & DISCUSSION
Orphan receptors were judged to be constitutively active if they significantly
affected cAMP dependent signaling (p < 0.05, according to a randomized complete block
ANOVA , 4 - 8 experiments) and additionally fulfilled at least one of the following
criteria: 1) 200% elevation over baseline reporter gene expression, 2) 40% inhibition of
baseline expression, or 3) 40% inhibition of expression stimulated by 3 µM forskolin.
These criteria were chosen to reflect thresholds large enough to minimize false-positives
due to receptor over-expression. Among the 40 orphan receptors evaluated, 75% (30)
met criteria for constitutive activity.
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GPCR’s are characterized by their interaction with specific transducer G proteins.
Gαs and Gαi play opposing roles in modulating cAMP levels in response to external
stimuli by mediating the activation and inhibition of adenylate cyclase respectively.
While this work did not directly measure association with either Gαs or Gα, changes in
gene expression under control of the cAMP-dependent response element (CRE) were
considered to indicate the involvement of pathways mediated by these transducers. Five
patterns of signaling were noted.

3.2.1. Group A: Constitutive Inhibition of Baseline and Forskolin Stimulated
CRE-Dependent Expression. As shown in Figure 3.1, the largest group of receptors
(17 of 40) exhibited significant constitutive inhibition of CRE-mediated gene expression
under both baseline and forskolin-stimulated conditions. This group is comprised of
GPR15, GPR17 variant 3, GPR18, GPR20, GPR25, GPR27, GPR31, GPR32, GPR45,
GPR55, GPR57 variant 1, GPR68, GPR83, GPR84, GPR132, GPR150, and GPR176. In
all cases, the statistical significance level was less than 0.01.
This behavior is similar to results obtained with the histamine receptor 4 (HRH4),
a receptor with known constitutive signaling through the Gαi pathway [38] using this
experimental design. While all 17 of these receptors inhibited gene expression by over
40%, five of them inhibited cAMP dependent gene expression by over 80%.
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Figure 3.1. Group A: Constitutive inhibition of baseline (B) and forskolin stimulated
CRE-dependent expression (F). The percent change of cAMP-dependent signaling in
CHO-K1 cells transfected with CRE-Luciferase reporter vector and an orphan G protein
coupled receptors is shown. Activity was measured as relative light units (RLU) and
normalized between experiments by dividing by the average of the 3 µM Forskolin
stimulated control within each plate. This value was then divided by the control for each
condition to obtain the fractional change, with a value of zero indicating no change from
control levels. Vertical dotted lines represent the minimum signaling threshold to be
scored as constitutively active within this study. Changes in basal cAMP dependent
expression are indicated by the light blue bars labeled “B”. Changes in expression in the
presence of 3 µM Forskolin (6 hour exposure) is indicated by the dark blue bars labeled
“F”. All receptors presented in this figure showed a significant treatment effect (** = p <
.01) and met the criteria adopted in this work to define constitutive activity.
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3.2.2. Group B: Constitutive Stimulation of Baseline and Inhibition of
Forskolin Stimulated Expression. As shown in Figure 3.2, this group is comprised of
receptors that are closely related in terms of amino acid homology: GPR6 and GPR12
[39]. A third member of this family (GPR3) produced extremely variable effects on
forskolin stimulated expression and its inhibition within these experiments was not
statistically significant (p = 0.072). Accordingly, it was included in group D.
Receptors in this group exhibited constitutive stimulation of CRE-mediated gene
expression under baseline conditions while inhibiting CRE-mediated gene expression
stimulated by 3 µM forskolin. Thus, these GPCRs can constitutively stimulate at least
one aspect of baseline cAMP-mediated signaling (i.e., CRE mediated gene expression)
while inhibiting high levels of cAMP-mediated signaling induced by an exogenous agent
(forskolin). It is possible that these receptors act to maintain an elevated but controlled
homeostatic level of cAMP by this pathway, a function known to be present in
maintenance of meiotic arrest in oocyte development [40].
3.2.3. Group C: No Effect on Baseline Expression but Inhibit Forskolin
Stimulated Expression. As shown in Figure 3.3, this group is comprised of GPR4,
GPR26, GPR61, GPR62, GPR78, GPR101, and GPR119. These receptors did not alter
baseline signaling enough to meet criteria for constitutive activity, although they all
inhibited CRE mediated gene expression stimulated by 3 µM forskolin by at least 40%.
In this way, they are similar to results obtained with a constitutively active mutant
version of the M2 acetylcholine receptor, which is capable of signaling through both the
Gαs and Gαi pathways [12,13].
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While baseline stimulation did not meet criteria for constitutive activity as defined
in this study, many of the receptors in this group produced a very significant “block” and
“treatment by block” effect (p < 0.01). Further measurements may reveal constitutive
activation of cAMP signaling under other conditions.

Figure 3.2. Group B: Constitutive stimulation of baseline (B) and constitutive inhibition
of forskolin stimulated CRE-dependent expression (F). The percent change in cAMP
dependent signaling in CHO-K1 cells transfected with CRE-Luciferase reporter vector
and various orphan G protein coupled receptors is shown. Vertical dotted lines represent
the minimum signaling threshold to be scored as constitutively active within this study.
Activity was measured, normalized and graphed as described in the legend to Figure 3.1.
Changes in basal cAMP dependent expression are indicated by the light blue bars labeled
“B”. Changes in expression in the presence of 3 µM Forskolin (6 hour exposure) is
indicated by the dark blue bars labeled “F”. Members of this group showed a significant
treatment effect (** = p < .01) and met the criteria adopted in this study to define
constitutive activity.
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Figure 3.3. Group C: No effect on baseline (B) and constitutive inhibition of forskolin
stimulated expression (F). The percent change in cAMP dependent signaling in CHO-K1
cells transfected with CRE-Luciferase reporter vector and various orphan G protein
coupled receptors is shown. Activity was measured, normalized and graphed as
described in the legend to Figure 3.1. Vertical dotted lines represent the minimum
signaling threshold to be scored as constitutively active within this study. Changes in
basal cAMP dependent expression are indicated by the light blue bars labeled “B”.
Changes in expression in the presence of 3 µM Forskolin (6 hour exposure) is indicated
by the dark blue bars labeled “F”. Members of this group showed significant treatment
effect (** = p < .01) but did not meet criteria for constitutive activation of 200%
stimulation over baseline expression levels (B). All members displayed constitutive
inhibition (40% or more) of 3 µM forskolin stimulated expression (F).
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3.2.4. Group D: Stimulation of Baseline Expression but No Inhibition of
Forskolin Stimulated Expression. As shown in Figure 3.4, this group is comprised of
GPR3 and GPR65 along with the closely related GPR21 and GPR52 [39]. These
receptors exhibited constitutive stimulation of baseline cAMP dependent signaling
without any constitutive inhibition of the signaling stimulated by 3 µM forskolin. This is
similar to CRE-mediated responses noted in the constitutive mutant of the M3 human
muscarinic acetylcholine receptor that signals through Gαq and Gαs activation without
activating the Gαi pathway.

Figure 3.4. Group D: Stimulation of baseline (B) but no change of forskolin stimulated
expression (F). The percent change in cAMP dependent signaling in CHO-K1 cells
transfected with CRE-Luciferase reporter vector and various orphan G protein coupled
receptors is shown. Activity was measured, normalized and graphed as described in the
legend to Figure 3.1. Vertical dotted lines represent the minimum signaling threshold to
be scored as constitutively active within this study. Changes in basal cAMP dependent
expression are indicated by the light blue bars labeled “B”. Changes in expression in the
presence of 3 µM Forskolin (6 hour exposure) is indicated by the dark blue bars labeled
“F”. Members of this group showed a significant treatment effect (* = p < .05, ** = p <
.01) and an increase of CRE-mediated gene expression of more than 200% under baseline
conditions (B), but did not affect gene expression stimulated by 3 µM forskolin (F).
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3.2.5. Group E: Non-Responders with No Constitutive Activity. As shown in
Figure 3.5, this group is comprised of the remaining 10 orphan receptors: GPR1, GPR19,
GPR22, GPR34, GPR35, GPR39, GPR63 variant 2, GPR82, GPR85, and GPR87.These
receptors lacked constitutive activity insofar as they failed to either have a significant
treatment effect or meet at least one of the three criteria for constitutive activity (i.e.,
200% baseline stimulation, 40% inhibition of baseline, or 40% inhibition of forskolinstimulated activity). Thus, not all orphan receptors exhibit constitutive signaling by
criteria established in this work. Accordingly, the constitutive activity noted is unlikely to
be due to an artifact arising solely from overexpression of receptor proteins in this
system.
Several of the receptors in this group displayed large fluctuations in response
from plate to plate, resulting in either loss of a significant treatment affect, or very
significant “block” and/or “treatment by block” effect (p < .01). The reasons for this
variability are not understood but suggest the presence of undefined variables in these
multistep pathways.
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Figure 3.5. Group E: No constitutive activity. The percent change in cAMP dependent
signaling in CHO-K1 cells transfected with CRE-Luciferase reporter vector and various
orphan G protein coupled receptors. Activity was measured, normalized and graphed as
described in the legend to Figure 1. Vertical dotted lines represent the minimum signaling
threshold to be scored as constitutively active within this study. Changes in basal cAMP
dependent expression are indicated by the light blue bars labeled “B”. Changes in
expression in the presence of 3 µM Forskolin (6 hour exposure) is indicated by the dark
blue bars labeled “F”. Receptors in this group failed to meet either study criteria of a
significant treatment effect (p value listed in red, * = .05, ** = .01) and/or threshold for
constitutive signaling.
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3.3. CONCLUSIONS
The purpose of these experiments was to identify the prevalence of constitutive
activity in the cAMP-dependent signaling pathway within 40 Class-A orphan GPCRs
using a luciferase-linked gene expression system. The activities examined were 1)
stimulation of baseline signaling, 2) inhibition of baseline signaling, and 3) inhibition of
forskolin-stimulated signaling. While 10 of the 40 receptors examined did not display
constitutive activity, cAMP-dependent constitutive activity was observed in 75% of the
orphan class-A receptors transiently expressed in CHO-K1 cells. Five groups of receptors
were defined reflecting different effects on baseline and forskolin-stimulated expression.
Constitutive inhibition of cAMP-dependent signaling was much more common than
stimulation (26 vs. 6 receptors), possibly reflecting cytotoxicity associated with high
levels of cAMP activity.
Receptors that are closely related on the basis of amino acid homology displayed
similar response patterns. For instance, the closely related GPR3, GPR6, and GPR12 all
stimulated baseline cAMP-dependent signaling while GPR6 and GPR12 both inhibited
forskolin activated signaling. Similarly, receptors in a second closely related group,
GPR21 and GPR52, both stimulated cAMP-dependent signaling without inhibiting
activity in the presence of forskolin. These results indicate that constitutive signaling is
an important physiological property of most of the remaining orphan class-A GPCRs and
may be a reason that many of their native ligands remain elusive. This suggests that a
search for inverse agonists may be the most effective approach to understanding their
physiological roles as well as selecting targets for pharmacological intervention.
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4. SUMMARY, DISCUSSION, AND IMPACTS

Examination of CRE-dependent gene expression as a measure of constitutive
activity in 40 different orphan class-A G protein coupled receptors is so broad a subject
that a review of pertinent background would be of limited use without the inclusion of the
results found within this work. Table 4.1 summarizes discussion found below, with
empty cells indicating no relevant data to report. Each subsection following reviews the
literature as pertaining to each individual Orphan GPCR in question, including discussion
of impacts of results found here-in.

Table 4.1. Summary of results and impacts.
GPR

Agree with literature?

CA?

1
3
4
6
12
15
17v3
18
19
20
21
22
25
26
27
31
32
34

Yes
Yes
Gαs, but not CA
Yes
Yes
Yes
Yes
Yes
Yes
Yes

No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes (Gαq)
Yes
Yes (Gαq)
Yes
Yes
Yes
Yes (Gαq)
Yes
Yes

Yes (Removed Outlier)
Gαs, but not CA

Yes

Impacts

First to claim CA Gαi
First to claim CA Gαi
First to claim CA Gαi
First to claim CA Gαi

First to claim CA Gαs
First to claim any CA
First to claim CA Gαi
First to claim CA Gαi
First to claim CA at all
First to claim CA at all
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Table 4.1. Summary of results and impacts cont…
GPR

Agree with literature?

35
39
45
52
55
57v1
61
62
63v2
65
68
78
82
83
84
85
87
101
119
132
150
176

Yes
Yes (Removed Outlier)
Yes

Gαs, but not CA
Yes
Yes
No
No Gαs CA
Yes
No
Yes

CA?
Yes (Gα12)
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes (Gαs)
Yes

Impacts
First to claim CA Gαi
First to claim CA Gαi
First to claim CA Gαs
First to claim CA Gαi
First to claim CA Gαi
First to claim CA Gαi
First to claim CA Gαi

First to claim CA Gαi
First to claim CA Gαi
More investigation is needed
No Gαs; First to claim CA Gαi
More investigation is needed

Yes
Gαs, but not CA
No
No Gαi, or CA

Yes
Yes (Gαs)
Yes
Yes
Yes

First to claim CA Gαi
No Gαs; First to claim CA Gαi
First to claim CA Gαi
First to claim CA Gαi
First to claim CA Gαi

4.1. GPR1
A homolog of GPR1 in plants has been found to play a role in the formation and
maintenance of mycorrhiza interactions [41] via increase in cAMP. Plants with this gene
knocked out had very limited ability to interact with its fungal counterparts. These
limitations were removed via the exogenous stimulation of cAMP. Further studies
continued to implicate this orphan as involved in the cAMP dependent signaling
pathways expressed under nutrient (nitrogen) starvation [42] and suggest that it may act a
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glucose/sucrose sensor in yeast [43] [44]. Investigation of this orphan in animals did not
reveal a specific pathway but did show an up-regulation in human-smooth muscle in
response to LDL cholesterol exposure [45].
While orphan G protein coupled receptor 1 (GPR1) has been researched by
multiple groups previously, no mention of specific constitutive activity was found. This
is supported by this work, which did not reveal any significant impact on cAMP
dependent signaling and scored this receptor in Group E: Non-responders.

4.2. GPR3
GPR3 is the first member of the “3-6-12 family”, a closely related group of
receptors along with its two “siblings”: GPR6 and GPR12 [39]. This orphan has also
shown the ability to elevate cAMP levels in multiple studies, although some go so far as
to assume it is due to simple over-expression of the receptor [46]. It retains a high degree
of homology between species and has been shown to act to constitutively increase cAMP
levels in HEK293 cells [47] via transfection. Evidence that it may be constitutively
signaling beyond the phenomenon of overexpression is found in its ability to maintain
high levels of cAMP in Xenopus laevis oocyte development, a condition critical to their
meiotic arrest [40].
The search for endogenous ligands for this receptor has led to the proposal that it
and its siblings are activated by short chain free fatty acids (FFA) [48] and the proposal
of an inverse-agonist with activity specific to GPR3 without affecting GPR6 and GPR12
[49].
The results of this study agree with previous findings of constitutive elevation of
cAMP as indicated by a 428% increase in basal cAMP dependent expression of the
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luciferase reporter vector. The response of this orphan under the influence of artificial
stimulation via 3 µM Forskolin are less clear. While a majority of plates surveyed did
show inhibition of the forskolin stimulation well above the 40% minimum, the range was
too large to maintain statistical significance. Previous evidence of this inhibitory
behavior has not been shown for this orphan and could constitute a novel finding with
further investigation.

4.3. GPR4
Originally isolated in 1995 [50], GPR4 was not highly studied until a few years
later. It has subsequently been shown to constitutively inhibit ERK1/2 activation [51],
although a direct method was not resolved. Additional studies revealed increased
activation of signaling via both the serum response element (SRE) and the cAMP
response element (CRE) [52]. The search for native agonists to this receptor has led to
the proposal that it may be activated by sphingosylphosphorylcholine (SPC) [53], as well
as glucose and some individual amino acids [54]. Further investigation revealed that
while the previous molecules do have an impact on GPR4 signaling, its primary function
was as a pH sensor that coupled to Gαs, Gαq/11, and Gα13 [55]. This was supported by the
identification of specific histidine residues that undergo protonation when exposed acid
conditions up to and including physiological pH [56].
While this work does reveal some stimulation of cAMP, it did not meet criteria
required to be considered constitutively active. Inhibition of 3 µM Forskolin (-86%) did
meet all criteria and would amount to the first evidence that this orphan receptor may
couple to Gαi or other inhibitory mechanisms.
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It is worth noting in this first example that the use of the term constitutive for this
receptor is somewhat argumentative. This term is used to infer “agonist independent”
signaling. It is left to the individual researcher to decide if the multiple protonation steps
required to induce an active conformation of this receptor constitutes “agonist” activity.

4.4. GPR6
Another member of the 3-6-12 family, GPR6 has been shown to have a high
affinity for sphingosine-1-phospate as a potential ligand and to constitutively increase
cAMP in its absence as well [48]. Further study of this potential agonist has resulted in
relative agreement, but in one particular case also revealed a single incident of its
signaling being sensitive to pertussis toxin [57]. Studies done in-vivo and in-vitro have
also implicated this orphan as having an impact in stimulation of neurite outgrowth and
counteracting myelin inhibition [58] as well as being capable of signaling from internal
compartments after being internalized from the cell membrane [59].
This work supports previous assertions that GPR6 constitutively stimulates cAMP
dependent signaling compared to baseline (295%) but also reveals its potential to inhibit
Forskolin stimulation of cAMP dependent signaling as well (-57%). This would support
the findings stated above regarding pertussis sensitivity, a toxin that acts to specifically
inhibit members of the Gαi family.

4.5. GPR12
The last member of the highly constitutively active “3-6-12 family”, GPR12
behaves very similarly to its siblings with respect to elevating cAMP levels but it has
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been found to have impacts on calcium mobilization as well [60]. It is upregulated in
response to fluid sheer stress in vascular endothelial cells [61] and has a pertussis
sensitive response to exposure of sphingosylphosphorylcholine (SPC) [62].
Results of this work agree that this receptor is capable stimulating (223%), and
inhibiting (-48%) cAMP dependent signaling in a constitutive manner, although it would
be the first to claim such inhibition is constitutive and not agonist dependent.

4.6. GPR15
GPR15 was first cloned in 1996 [63]. It has since been implicated in intestinal
sensitivity to gp120, a small protein found in the blood of HIV positive patients.
Evidence that it is capable of signaling via Gαi and Gαq pathways was found via pertussis
sensitive [64], and phospholipase inhibition [65] after gp120 exposure respectively. It
was suggested that high levels of expression of this orphan receptor may help target those
cells for potential immune responses [66].
While this work supports these findings- with GPR4 showing strong inhibition of
cAMP dependent signaling under both baseline (-79%) and 3 µM Forskolin stimulation
(-66%), it is the first to reveal constitutive activity of this receptor.

4.7. GPR17 VARIANT 3
GPR17 is a putative uracil/cysteinyl-leukotrienes receptor that can signal via
inhibition of cAMP and calcium mobilization [67]. It is expressed in neuronal cells in
response to damage and to mediate local repair mechanisms [68]. The receptor is rather
promiscuous and capable of signaling via Gαi/Gαs/Gαq pathways [69]. Inhibitory
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signaling via Gαi has been additionally confirmed via luciferase and other methods [70],
[71] with one study finding as high as 80% inhibition of forskolin stimulation in CHO
cells, although they were not able to isolate the signaling to GPR17 specifically [72].
This work supports the assertion that GPR17 is a constitutively active orphan
receptor with respect to Gαi activation with significant inhibition cAMP dependent
signaling under baseline (-87%) and forskolin stimulated (-92%) conditions.

4.8. GPR18
The murine homolog of GPR18 was first isolated in 1996 [73]. A potential
agonist for this orphan was proposed until 2006 when N-arachidonylglycine (NAGly)
was shown to increase calcium concentration and inhibit forskolin induced cAMP
production in CHO cells in a pertussis sensitive manner [74]. This orphan is known to be
constitutively active in melanomas, acting as an apoptosis inhibitor [75]. It plays the
reverse roll in macrophage apoptosis, signaling cell death [76]. Both of these rolls were
mediated via Gαi pathways. Work on alternate cannabinoid compounds as potential
agonist showed differential activation of Gαq / Gαi signaling suggesting biased agonism
in pathway selection [77].
This work supports the assertion that GPR18 constitutively signals via the Gαi
pathway, showing a reduction of baseline cAMP dependent signaling (-44%) and
forskolin stimulated signaling (-55%) respectively.

40
4.9. GPR19
GPR19 was first mapped on a human chromosome in 1999 [78]. It is expressed
in neuronal cells during mouse embryogenesis and plays its most significant role in early
development [79]. Expression of this orphan is also increased in metastatic melanomas
although its impact on the tumor cells is unknown [80]. It has been previously evaluated
via a study that assumed constitutive signaling due to overexpression, where in it elevated
calcium levels in the presence of a Gq/i chimeric [60]. This chimeric protein couples to
receptors with an affinity for Gαi, but signals via calcium mobilization as a native Gαq.
This work did not reveal any significant cAMP dependent activity of GPR19 and
it was scored as a “non-responder”. The loss of statistical significance under forskolin
stimulation was due to extreme variability of response (as shown in Figure 4.1). This,
coupled with the extreme significance of the “block” and “treatment-by-block” analysis
(p << .01 in both cases) suggests that further study of this receptor is merited.

4.10. GPR20
GPR20 is a member of the G protein coupled receptors for which exceptionally
little is known. It was first cloned and mapped on a human chromosome in 1997 [81].
And it constitutively activates Gαi in a pertussis sensitive manner [82].
This work supports the above assertion with an inhibition of baseline signaling
(-84%) and forskolin stimulated signaling (-91%).
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Figure 4.1. Results of five experiments with GPR19. The percent change of cAMPdependent signaling in CHO-K1 cells transfected with CRE-Luciferase reporter vector
and orphan G protein coupled receptors 19 (GPR19). Activity was measured as relative
light units (RLU) and normalized between experiments by dividing by the average of the
3 µM Forskolin stimulated control within each plate. This value was then divided by the
control for each condition to obtain the fractional change, with a value of zero indicating
no change from control levels. Criteria for constitutive activity in this study were 200%
stimulation or -40% inhibition. Changes in basal cAMP dependent expression are
indicated on the left under “Baseline”. Changes in expression in the presence of 3 µM
Forskolin (6 hour exposure) is indicated on the right under “3 uM Forsk”. Significant
divergence from control expression is marked as calculated via Students T-test (n=4, * =
p < .05, ** = p < .01).

4.11. GPR21
GPR21 was first cloned in 1993 [83], and then mapped on a human chromosome
in 1997 [81]. It was a member of the group studied under the assumption that overexpression led to constitutive signaling. This resulted in a mobilization of calcium
indicative of a Gαq response [60]. Subsequent work has suggested it plays a role in
weight and metabolism via reducing insulin sensitivity, with GPR21 knockout mice not
getting obese under high caloric diets [84] [85].
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This work suggests for the first time that GPR21 is constitutively active via
cAMP dependent pathway; increasing baseline cAMP dependent expression by 421%.

4.12. GPR22
GPR22 was first cloned and mapped in 1997 [81]. Evidence exists that it may
couple exclusively to Gαi therefore inhibiting cAMP, playing a role in the regulation of
cardiac function [86]. It has been implicated as a risk factor for the development of
osteoarthritis based on chromosomal location [87], but other studies have called that
conclusion into question [88]. It has a significant role in axis formation and knockout of
GPR22 leads to defective axis formation and changes in cilia structure within the
Kupffer's vesicle of zebra fish [89]. These findings suggest it functions beyond simple
cardiac regulation.
This work scored GPR22 as a “Non-Responder”- although the baseline results
were varied enough to loose statistical significance. This was primarily due to a single
plate with highly divergent responses. If this outlier is removed, the remaining four
experiments would be show an inhibition of baseline signaling (-34%) and an inhibition
of forskolin stimulated signaling (-46%). These adjusted values would have a significant
treatment factor (p < 0.01) and would meet criteria for Gαi activation in agreement with
the previous studies above.

4.13. GPR25
GPR25 is another orphan receptor for which information is very limited. It was
discovered and mapped to chromosome 1 in 1997 [90] and its expression is regulated
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during exposure to LDL particles within smooth muscles [45]. No mention of a pathway
or mechanism for this result is explained.
This work is the first to suggest that GPR25 is a constitutively active orphan
GPCR that acts to significantly inhibit cAMP levels under both baseline (-87%) and
forskolin stimulated (-81%) conditions.

4.14. GPR26
GPR26 was first cloned and identified in 2000 [91], and then mapped in 2001
[92]. It was able to elevate cAMP levels in a study that assumed overexpression would
lead to constitutive activation [60]. It was found to be constitutively active in HEK293
cells where it elevated cAMP levels [93]. Another study found that GPR26 is
epigenetically silenced in human glioblastomas and was capable of increasing cAMP in
HEK cells in-vitro [94]. And knockout of GPR26 reduced cAMP levels in central
amygdala resulting in mice showing signs of severe depression [95].
This work agrees with the previous studies asserting the ability of GPR26 to
stimulate cAMP dependent signaling under baseline conditions, although it did not meet
criteria to be considered “constitutive” (only 170% increase). It did meet criteria for
constitutive activity via inhibition of forskolin stimulation (-57%) and this work is the
first to suggest that GPR26 may also play a role in cellular metabolism via this pathway.

4.15. GPR27
GPR27 was first discovered in 1998 [96]. It is highly conserved between human,
monkey, and rat homologs and may play a role in neural plasticity [97]. Overexpression
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in 293T cells increases IP3 levels and siRNA knockout in MIN6 cells reduces IP3
suggesting activation of the Gαq pathway [98]. No other studies referencing specific
mechanism, or constitutive activity outside of the Gαq /IP3/Calcium pathway was found.
This work is the first to suggest that GPR27 may constitutively signal through the
Gαi pathway due to high levels of inhibition under both baseline (-74%) and forskolin
stimulated conditions (-68%).
.
4.16. GPR31
GPR31 was first isolated in 1997 [99]. It has been suggested that the lipid
molecule 12-(S)-hydroxy-5,6,10,14-eicosatetraenoic acid (HETE) may couple with this
receptor [100], but no mention of which pathway is stimulated was suggested.
This work is the first to suggest that GPR31 may constitutively signal through the
Gαi pathway due to high levels of inhibition under baseline (-74%) and forskolin
stimulated conditions (-71%).

4.17. GPR32
GPR32 was first cloned in 1998 [101]. Its expression is regulated in smooth
muscles during exposure to LDL cholesterol particles [45] and may respond to
“resolvins”, lipid molecules that are part of inflammatory signaling [102] [103]. When
triggered with these molecules it activates MapK and Nf-kB pathways [104] suggesting
activation via the G12 family. One study also found possible Gαq activation via calcium
mobilization [105]. While some study has been done on the potential impact of GPR32
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activity on inflammatory signaling, no work has been done to show if this receptor is
constitutively active or signals via the Gαs / Gαi cAMP dependent pathways.
This work is the first to suggest that GPR32 may constitutively signal through the
Gαi pathway due to high levels of inhibition under baseline (-69%) and forskolin
stimulated conditions (-71%).

4.18. GPR34
GPR34 was discovered in 1999 [106] and subsequently mapped in 2000 [107].
Lysophosphatidyl-L-serine (LysoPS) may be an agonist, showing a dose dependent
inhibition of forskolin-stimulated cAMP in GPR34 expressing CHO cells, and possibly
playing a role in mast cell degranulation [108]. Subsequent studies showed that the
specificity for LysoPS is dependent on the Serine residue to activate Gαi signaling [109]
and that it may [110], or may not be the native ligand for the human ortholog [111]. It
has also been suggested that GPR34 may play a role in gastric cancer cell proliferation
and migration with knockout GPR34 cancer cell lines showing considerably lower
measurements under both of those metrics [112].
This work scored GPR34 as a “Non-Responder”. Unlike a few other members of
this group, GPR34 did not show a sizable elevation or inhibition of cAMP dependent
signaling in the majority of its experiments. Removing one experiment that was a
significant outlier, the remaining experiments can be seen in Figure 4.2 below. This,
along with the few orphans who behaved similarly- is the basis for the assertion made in
this work that the constitutive activity found here-in is not due to simple over-expression,
but an inherent property of the individual receptor in question.
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Figure 4.2. “Non-Responder” GPR34 results with single outlier removed. The percent
change of cAMP-dependent signaling in CHO-K1 cells transfected with CRE-Luciferase
reporter vector and orphan G protein coupled receptors 34 (GPR34). Activity was
measured as relative light units (RLU) and normalized between experiments by dividing
by the average of the 3 µM Forskolin stimulated control within each plate. This value
was then divided by the control for each condition to obtain the fractional change, with a
value of zero indicating no change from control levels. Criteria for constitutive activity in
this study were 200% stimulation or -40% inhibition. Changes in basal cAMP dependent
expression are indicated on the left under “Baseline”. Changes in expression in the
presence of 3 µM Forskolin (6 hour exposure) is indicated on the right under “3 uM
Forsk”. Significant divergence from control expression is marked as calculated via
Students T-test (n=4, * = p < .05, ** = p < .01).

4.19. GPR35
GPR35 was discovered in 1998 [96]. Kynurenic acid was suggested as a potential
ligand for the rat homolog in 2006. Exposure to this ligand inhibited calcium channels in
rat sympathetic neurons, and induced a calcium response when transfected with a
chimeric Gαq/i discussed previously [113]. These effects were pertussis toxin sensitive,
further indicating coupling with Gαi [114]. It has since been found to be rather non-
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specific in its agonist affinity [115] [116] including tyrphostin analogs [117], Aspirin
metabolites [118], natural phenols [119].
This work scored GPR35 as a “Non-Responder”. It did not meet study criteria for
constitutive signaling. This is in agreement with previous studies which have all been
based on different agonist dependent experiments. These findings again support the
assertion of this work that the results found here-in are not the simple outcome of overexpression.

4.20. GPR39
GPR39 was first cloned in 1997 [120]. Signaling was originally thought to be due
to a proposed agonist, obestatin, but was discovered to be caused instead by zinc ions
[121]. Exposure to free zinc ions increased cytosolic calcium levels in cells transfected
with GPR39 in a manner that was abolished by a PLC inhibitor [122]. HEK293T cells
transfected with GPR39 showed constitutive activation of a SRE-Luciferase reporter
which was not sensitive to obestatin [123]. These findings wound indicate that this
receptor could signal through both Gαq and Gα12 pathways. Evidence supporting this was
found via disruption of the highly conserved di-sulfide bridges of this GPCR, diminishing
agonist induced signaling via Gαq dependent calcium mobilization, but increasing
constitutive SRE dependent signaling. Disruption of a second di-sulfide bridge, unique to
GPR39, caused the inverse effect- greatly increasing agonist affinity and potency while
diminishing constitutive SRE signaling [124]. There was a single study that found
GPR39 was able to elevate cAMP levels in the cell, but in a zinc-dependent manner
[125].
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This work scored GPR39 as a “Non-Responder”: unable to reach study criteria to
be considered constitutively active (-40%). Even so, three out of four plates with GPR39
did show a significant inhibition of cAMP dependent signaling that remains statistically
significant (p < .01). Removal of the single outlier would move this orphan into group A,
significant inhibition of cAMP dependent signaling under both baseline (-63%) and
forskolin stimulation (-57%). If so- it would present the first evidence of potential
constitutive activation via an inhibitory pathway and in the absence of its primary
indicated agonist; zinc ions.

4.21. GPR45
GPR45 was discovered in 1999 [106] and is expressed highly in the brain [126].
This work adds the first evidence of potential Gαi activity via the strong suppression of
cAMP dependent signaling under baseline (-87%) and forskolin stimulated conditions (94%).

4.22. GPR52
GPR52 was first identified and cloned in 1999 [127]. It is well conserved among
vertebrate species, couples to Gαs proteins and responds to reserpine, an antipsychotic
drug. In the presence of this agonist cAMP levels increased in a dose dependent manner
but no evidence of constitutive basal signaling was found [128]. In the presence of a
novel agonist, GPR52 was shown to inhibit D2 receptor signaling and activate D1
signaling via cAMP accumulation [129].
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This work agrees with previous findings indicating activation of cAMP dependent
signaling but is the first to show constitutive activation under basal signaling, let alone to
the degree measured here-in (850%).

4.23. GPR55
First identified and cloned in 1999 [127], GPR55 was originally proposed as a
cannabinoid receptor [130]. Pathway analysis revealed its primary function under agonist
stimulation was via calcium mobilization [131]. Subsequent identification of additional
cannabinoid compounds, with special affinity for delta(9)-THC, that elicited calcium
mobilization solidified this as its primary mode of signaling [132]. This lead to
subsequent screens for alternative agonists [133] and antagonists [134] but these were
only watching the Gαq/calcium pathways. Understandably for a receptor with such a
large repertoire of suggested binding agents, the ability to recruit and signal via the Gαq
pathway was determined to be highly agonist specific [135]. Additional information
complicating the understanding of this “orphan” receptor’s signaling pathway was found
in its ability to hetero-dimerize with other cannabinoid GPCRs, thus shifting their
signaling to its pathway [136].
This orphan receptor remains so in name only due to the lack of consensus on the
primary endogenous ligand. Out of all of the research covered in this work, there was no
mention of constitutive activity. The ability to significantly inhibit both baseline (-80%)
and forskolin stimulated (-78%) cAMP dependent gene expression as shown here-in is
the first time such evidence has been seen.
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4.24. GPR57 VARIENT 1
GPR57 was first mapped in 2000 [91]. It has been suggested that it plays a role in
febrile seizures due to its location on chromosome 6 [137], and it is upregulated for
excretion in multiple types of human cancer cells lines [138].
This work is the first to suggest a pathway of activity for this receptor, and to
show it is capable of constitutively inhibiting baseline (-40%) and forskolin stimulated (44%) cAMP dependent gene expression.

4.25. GPR61
GPR61 was first identified in 2001 [139], and is expressed to a high degree in
different areas of the brain [140]. It couples with Gαs constitutively and is dependent on
the presence of the N-terminal 20 amino acids in order to maintain its activity, potentially
acting as its own intra-molecular ligand [141]. Subsequent research suggested it plays a
role in obesity [142] and Type 2 diabetes [143].
While this work does not agree with the assertion of constitutive Gαs coupling
(157% increase did not meet thresholds for constitutive activity) it is the first to suggest
that it may have an alternative role in the inhibition of cAMP via its suppression (-57%)
of elevated cAMP levels due to forskolin stimulation.

4.26. GPR62
GPR62 was first discovered in 2001 and was found to be expressed highly in the
brain [140]. Little else is known about this orphan receptor.
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This work is the first to suggest it may be active physiologically via the
constitutive inhibition of cAMP dependent signaling, shown by its ability to inhibit (64%) forskolin dependent expression. The lack of inhibition under baseline conditions
would suggest that it either couples to Gαs and Gαi as the M2 muscarinic receptor, or that
its Gαi coupling is cAMP dependent.

4.27. GPR63 VARIANT 2
First identified in 2001 [140], it has been suggested that this orphan receptor binds
to sphingosine 1-phosphate (S1P) causing an inhibition of cAMP via Gαi [144]. No other
mention of pathway or constitutive activity was found.
This work scored this receptor as a “Non-Responder”, with no significant
stimulation of baseline cAMP dependent signaling and the loss of a statistically
significant treatment effect under forskolin stimulation. This is further evidence that the
scoring methodology used in this work is not due to simple over-expression of these
receptors within this system.

4.28. GPR65
GPR65, also known as TDAG8, was first cloned in 1998 [145]. It is now known
to be a “proton sensor” that stimulates cAMP under physiological pH and lower in-vitro
[146]. Elevation of cAMP in cells expressing GPR65 enhanced cellular viability in mice
[147]. And the proton sensor action of GPR65 may play a role in superoxide inhibition of
neutrophils [148].
This study scored GPR65 as a constitutively active Gαs signaler due to its
stimulation of baseline cAMP dependent expression (317%) and its lack of any ability to
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inhibit forskolin stimulation. While conditions found within this work were controlled
for pH between plates via the carbonate buffer and 5% CO2 injection during growth, as
stated previously it is arguable that the signaling found here-in is not “constitutive”.

4.29. GPR68
GPR68, also known as OGR1, was first mapped in 1996 [149] and was
subsequently shown to constitutively increase IP levels under physiological pH and lower
[150]. Other studies found that this orphan was also able to stimulate the accumulation of
cAMP, in addition to the accumulation of IP, suggesting coupling to both Gαs and Gαq,
but only under conditions slightly below physiological pH [151]. Gαs coupling was
found to be unlikely during further examination, as the cAMP production was abolished
in the presence of a PLC-inhibitor, suggesting it was due to cross-talk and not direct
stimulation of the Gαs protein itself [152].
This work disagrees with previous assertions of cAMP stimulation, scoring this
orphan instead as a constitutive inhibitor of cAMP dependent signaling under baseline
(-48%) and forskolin stimulated (-73%) conditions. Previous studies did not examine the
ability of this orphan to abolish artificially elevated cAMP levels stimulated via an
exogenous agent (forskolin) but also did not mention any significant lowering of basal
cAMP levels.
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4.30. GPR78
GPR78 was first mapped in 2001 [92]. It was found to be constitutively active in
HEK293 cells coupled to increase in cAMP as predicted in hidden Markov model
method. For this reason, potential inhibition vs. Gαi was not assayed [93].
This work is the first to suggest constitutive activation of Gαi via the inhibition
(-73%) of forskolin stimulated cAMP dependent expression. The lack of inhibition under
baseline conditions agrees with either a competitive interaction of this orphan with a Gαs
/ Gαi nature, such as the human M2 muscarinic receptor, or that coupling with Gαi in a
constitutive manner may be cAMP dependent.

4.31. GPR82
First mapped in 2001 [92], GPR82 deficient mice had a lower body weight,
triglyceride level, and increased insulin sensitivity with no difference in
respiratory/metabolic rates [153].
This work scored GPR82 as a “Non-Responder” in that it did not reach thresholds
to be considered constitutively active. Even so, the treatment effect was very statistically
significant, along with the “block” and “treatment by block” measurements (p < .01 in all
cases). Examination of the individual experiments reveals why. Elimination of one
outlier experiment, where both conditions showed stimulation above the 200% cut-off,
leaves the remainder as shown in Figure 4.3. While there is usually only minor impact on
baseline cAMP dependent signaling, there seems to be an intermittent phenotype that
shows high levels of inhibition of forskolin stimulated cAMP dependent expression.
Even with this removal, the average response still does not meet criteria for constitutive
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activity (only -39% under forskolin stimulation, although still significant treatment effect,
p < 0.01) it is worth noting that there may be something more to the story of this very
unknown orphan GPCR.
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Figure 4.3. “Non-Responder” GPR82 results with single outlier removed. The percent
change of cAMP-dependent signaling in CHO-K1 cells transfected with CRE-Luciferase
reporter vector and orphan G protein coupled receptors 82 (GPR82). Activity was
measured as relative light units (RLU) and normalized between experiments by dividing
by the average of the 3 µM Forskolin stimulated control within each plate. This value
was then divided by the control for each condition to obtain the fractional change, with a
value of zero indicating no change from control levels. Criteria for constitutive activity in
this study were 200% stimulation or -40% inhibition. Changes in basal cAMP dependent
expression are indicated on the left under “Baseline”. Changes in expression in the
presence of 3 µM Forskolin (6 hour exposure) is indicated on the right under “3 uM
Forsk”. Significant divergence from control expression is marked as calculated via
Students T-test (n=4, * = p < .05, ** = p < .01).
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4.32. GPR83
First cloned in 2000, its expression was induced by glucocorticoid exposure
[154], and is highly expressed in the forebrain [155]. It may play a role in the control of
feeding behavior, regulation of stress and emotional behavior, learning and memory, and
drug reinforcement and reward [156]. Pathway analysis of this orphan GPCR in mice
reveals basal Gαq activity without any change in cAMP levels, even in the presence of
forskolin. This same study also showed this orphan acts as a Zn(II) sensor via multiple
extracellular histidine residues [157]. The N-terminal end of GPR83 acts as its own
inverse-agonist, with deletion mutants increasing basal Gαq signaling via calcium
mobilization but does not impact cAMP dependent signaling [158].
While this work does not agree with previous findings in mice, CHO-K1 cells
transfected with GPR83 shows significant and sizable inhibition of baseline (-78%) and
forskolin stimulated (-70%) cAMP dependent signaling. This would be the first
suggestion of such activity.

4.33. GPR84
First discovered in 2001[159], it has been suggested as a medium chain free fattyacid (FFA) receptor, acting via calcium mobilization and cAMP inhibition [160]. Impacts
of FFA on metabolism, including consideration of GPR84 as a FFA receptor, has been
reviewed twice in recent history [161], [162].
This work agrees with previous work that GPR84 acts through Gαi inhibiting
cAMP dependent signaling of baseline (-44%) and forskolin stimulated (-54%)
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conditions. It is arguable if this activity is truly “constitutive” or if it is responding to
FFAs in the cell culture medium during the experiment.

4.34. GPR85
GPR85 is an orphan G protein coupled receptor expressed primarily in the brain
[163], plays a role in neural plasticity and is highly conserved between human, monkey,
and rat [97]. Over expression of this receptor in mice decreased brain size, and knockout mice showed increased brain size [164].
This work scored GPR85 as a “Non-Responder”, with the baseline expression not
even capable of holding statistical significant treatment effect. Even so, examination of
the experimental data (Figure 4.4) reveals a strong trend between two different responsesone that amounts to no effect among the first three experiments, and a significant
inhibition of cAMP dependent signaling in later experiments. What may have caused this
divergence in responses is unknown, but does flag this receptor as worthy of further
investigation.

4.35. GPR87
Data mining of previous studies discovered GPR87 in 2001 [159].
Lysophosphatidic acid (LPA) has been suggested as a potential agonist for GPR87, via
activation of a G protein fusion eliciting a calcium response [165]. It is over-expressed in
many cancer cells and knockdown of GPR87 has anti-proliferative affect [166]. This
work scored GPR87 as a “Non-Responder”. Along with others mentioned in this group,
the response of GPR87 is further evidence that this work is not measuring activity due
solely to the over-expression of the receptor. This supports the claim that the criteria
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used within this work as an effective means of measuring constitutive activity inherent in
the receptor itself.
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Figure 4.4. “Non-Responder” GPR85 results with single outlier removed. The percent
change of cAMP-dependent signaling in CHO-K1 cells transfected with CRE-Luciferase
reporter vector and orphan G protein coupled receptors 85 (GPR85). Activity was
measured as relative light units (RLU) and normalized between experiments by dividing
by the average of the 3 µM Forskolin stimulated control within each plate. This value
was then divided by the control for each condition to obtain the fractional change, with a
value of zero indicating no change from control levels. Criteria for constitutive activity in
this study were 200% stimulation or -40% inhibition. Changes in basal cAMP dependent
expression are indicated on the left under “Baseline”. Changes in expression in the
presence of 3 µM Forskolin (6 hour exposure) is indicated on the right under “3 uM
Forsk”. Significant divergence from control expression is marked as calculated via
Students T-test (n=4, * = p < .05, ** = p < .01).

4.36. GPR101
First mapped in 2001 [92], GPR101 is matched to Gαs via hidden Markov model
analysis and elevated CRE dependent luciferase expression in HEK293 cells, although no
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test for forskolin inhibition was done [167]. It has also been linked to acromegaly due to
single nucleotide polymorphism mutation [168].
This study agrees with the implication of Gαs signaling, although it did not meet
criteria for constitutive signaling, and is the first to show inhibition of forskolin
stimulated expression (-68%).

4.37. GPR119
First identified in 2002 [169], GPR119 has been highly studied as a target for
metabolic disorders including type 2 diabetes. Its remaining classification as an orphan is
due mainly to the ongoing search and disagreement as to its primary native agonist. For
example, Lysophosphatidylcholine (LPC) acts as a strong enhancer of rat pancreatic
insulin secretion in response to high concentrations of glucose via the simulation of
cAMP. LPC also increases cAMP in mouse pancreatic cell lines in a dose dependent
fashion. Exposure to siRNA specific to GPR119 blocked these effects [170].
Oleoylethanolamide and N-oleoyldopamine are potent agonists of GPR119, inducing
intracellular cAMP accumulation in both pancreatic and gut enteroendocrine cells [171].
These suggested agonists were found to have differential effect on GPR119 pathway
signaling preferentially activing cAMP or calcium mobilization [172]. GPR119 and its
implications for the treatment of type 2 diabetes and related metabolic disorders was
reviewed in 2009 [173], and again 2012 [174]. The search for potential agonists since has
concentrated on finding activating molecules that do not cause severe desensitization
during in-vivo studies [175]. Recent studies have noted constitutive activity of this
receptor that is Gαs dependent [176,177], and is highly dependent on multiple
extracellular residues [178].
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This work scores GPR119 as a constitutive inhibitor of forskolin stimulated
cAMP dependent signaling (-84%), but does not agree with recent findings indicating
constitutive Gαs pathway activation. It does not seem common among assumed Gαs
constitutive signalers to test if they can inhibit an exogenous cAMP stimulation
(forskolin). Given the nature of this orphan in regulation of cAMP dependent insulin
release the potential that it may constitutively signal via inhibitory pathways would
contribute to its homeostatic mechanism. This could also be explained via differences in
cell expression in CHO cells verses cells lines that natively express this orphan.

4.38. GPR132
GPR132, also known as G2A, has been suggested as a receptor for oxidized
FFAs- with a potential role in lipid overload and oxidative stress via calcium
mobilization [179]. It is also been suggested as a pH-sensor but is missing the Histidine
residues of its relatives (GPR4, TDAG8) and did not significantly elevate IP or cAMP
[146]. Further examination showed that it is not as sensitive to pH as its relatives, but
may signal through Gαi / Gαq / Gαs, and Gα13 to influence Migration, and apoptosis
[180]. Lysophosphatidyl-choline (LPC) binding to GPR132 can produce signaling via IP
& cAMP, though only the cAMP response is dose dependent [181]. Activation by 9hydroxyoctadecadienoic acid (9-HODE) in CHO-K1 cells showed Ca mobilization, IP3
increase, and inhibition of cAMP levels, suggesting activation of Gαi signaling pathways
[182]. Lysophosphatidyl-serine acts as an agonist for GPR132 causing an increase in
cAMP in macrophages and increased their ability to clear recruited neutrophils from
areas of inflammation [183].
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This work scores GPR132 as a strong inhibitor of baseline (-68%) and forskolin
stimulated (-70%) cAMP dependent signaling. This orphan is a highly studied G protein
coupled receptor that only remains an orphan due to the disagreement over the primary
native agonist coupled to its activation. Most of its agonist-dependent action seems to be
related to Gαq / Gαs signaling, the constitutive Gαi implicated within this work may be a
new function in maintaining low levels of cAMP until stimulated by agonists.

4.39. GPR150
First discovered in 2005 [184], GPR150 is a possible candidate for tumor biomarker as it was upregulated in 4 out of 15 different cancer types via methylation of its
promotor [185]. Structurally, it is related to gonadotropin releasing hormone receptors,
although no agonist has been suggested [39].
This work suggests for the first time that GPR150 is a strong constitutive inhibitor
of baseline (-85%) and forskolin stimulated (-78%) cAMP dependent expression. As
seen in Figure 4.5, the treatment effect of GPR150 being present in CHO-K1 cells is
significant and is similar to results seen in all members found in “Group A” in this work.

4.40. GPR176
GPR176 was first discovered in 1995 [186], and is regulated during smooth
muscle cholesterol synthesis but there is no mention of a pathway [45].
This work is the first to show that GPR176 is a strong constitutive inhibitor of
baseline (-88%) and forskolin stimulated (-89%) cAMP dependent expression.
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Figure 4.5. “Group A” GPR150 results. The percent change of cAMP-dependent
signaling in CHO-K1 cells transfected with CRE-Luciferase reporter vector and orphan G
protein coupled receptors 150 (GPR150). Activity was measured as relative light units
(RLU) and normalized between experiments by dividing by the average of the 3 µM
Forskolin stimulated control within each plate. This value was then divided by the
control for each condition to obtain the fractional change, with a value of zero indicating
no change from control levels. Criteria for constitutive activity in this study were 200%
stimulation or -40% inhibition. Changes in basal cAMP dependent expression are
indicated on the left under “Baseline”. Changes in expression in the presence of 3 µM
Forskolin (6 hour exposure) is indicated on the right under “3 uM Forsk”. Significant
divergence from control expression is marked as calculated via Students T-test (n=4, * =
p < .05, ** = p < .01).
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5. CONCLUSIONS

The following conclusions can be drawn from the data and analysis presented in
this work:


Gene expression assays are a viable and meaningful characterization method for
receptor signaling and can reveal promiscuity and constitutive activity of G
protein coupled receptors.
o This technique was able to characterize both wild-type and constitutively
active versions of all five members of the Muscarinic GPCR family in
agreement with canonical understanding.



This technique allowed for the experimental examination of 40 different orphan
class-A G protein coupled receptors to screen for the prevalence of cAMP
dependent constitutive signaling, revealing such activity in 75% of receptors
studied.



Constitutive inhibition of cAMP dependent signaling was much more common
than stimulation



Novel findings with respect to potential signaling pathways was found in 23
orphans, and otherwise agrees with previous findings where signaling pathway
has been examined.



Results of this work can be attributed to constitutive signaling and not simple over
expression of receptors.
o “Non-Responders” revealed patterns that suggest either a lack of
constitutive signaling or an un-resolved triggering condition (ie. agonists
dependent).
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Constitutive signaling is an important physiological property a majority of the
remaining orphan class-A GPCRs.
o The search for inverse agonists may be the most effective approach to
understanding their physiological roles as well as selecting targets for
pharmacological intervention
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